French Startup Orakl Oncology Raises €30Mn to Transform Cancer Drug Research

The funding round was co-led by Norrsken VC and Singular. New investors InfraVia Capital Partners, Serena, the Patient Autonome Fund managed by Bpifrance, Teampact Ventures and Plug and Play also participated.

Existing investors Verve Ventures VC, Speedinvest and HCVC also joined the round, showing continued support for the company's work in developing AI-based solutions for cancer drug research.

Dr. Fanny Jaulin, CEO and co-founder of Orakl Oncology, says: “For decades, we’ve developed cancer drugs without being able to reliably predict how they will behave in patients until they reach clinical trials. We believe the next breakthrough will come from making tumor and patient biology predictable. This funding will allow us to expand Orakl’s proven capabilities across more cancer types and pharmaceutical programmes to impact oncology more widely.”

Jeremy Uzan, co-founder and General Partner at Singular, adds: “Fanny, Gustave and Diane-Laure bring together a rare combination of expertise in cancer research, cell biology and computational biology, alongside a clear understanding of what the pharmaceutical industry needs. They’ve translated that expertise into a platform that combines real patient biology, experimental data and AI to predict how cancer drugs will perform in clinical trials. We’re proud to continue backing the team as they scale.”

Founded in 2023, Orakl Oncology is developing AI-powered virtual cancer patients to help predict how new cancer drugs may work before they enter clinical trials. The technology aims to give researchers a better understanding of how patients might respond to different treatments.

The company was spun out of the Gustave Roussy Institute. It combines lab-grown tumour samples taken from real patients with clinical and molecular data to build its technology and improve cancer drug research.

Read Also- SE3 Raises €27Mn Series A Funding Led by Accel to Expand Spatial AI Technology Across Europe